id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2022-E-2103-0005,FDA,FDA-2022-E-2103,Determination of Regulatory Review Period for Purposes of Patent Extension; EXKIVITY,Notice,Determinations,2023-12-08T05:00:00Z,2023,12,2023-12-08T05:00:00Z,2024-02-07T04:59:59Z,2023-12-08T13:46:28Z,2023-27004,0,0,090000648631602a
FDA-2022-E-2103-0004,FDA,FDA-2022-E-2103,Letter from FDA CDER to U. S. Patent and Trademark Office,Other,Letter(s),2023-12-01T05:00:00Z,2023,12,2023-12-01T05:00:00Z,,2023-12-01T19:53:14Z,,0,0,09000064862d450d